Forte Biosciences gains premarket after $150 mln equity raise
Forte Biosciences FBRX.O shares up 3.3% premarket to $27.13 after $150 mln overnight equity raise
Autoimmune diseases-focused biopharma co late Weds announced ~5.7 mln shares at $26.27, matching their last close
FBRX intends to use net proceeds for working capital and other purposes, including funding clinical development of its product candidates and other research activities
Guggenheim and Barclays joint bookrunners
Dallas, Texas-based FBRX has ~13.9 mln shares outstanding for ~$365 mln market cap prior to offering
Through Weds, stock down ~4% YTD. It closed at $5.70 a year ago
Of 6 analysts covering the stock, 1 rates "strong buy", 5 rate "buy"; median PT $59.50, according to LSEG data
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Musk’s XChat Is Coming to App Store, Meta, Apple and Finance World Are Trembling

Anthropic IPO 2026: What the Claude Mythos Release Delay Means for Investors and Stock Valuation

Microsoft Launches Its Own AI Models and Ditches OpenAI Dependence - Is MSFT Stock a Buy at $370?

Intel Stock's Rare Surge: What’s Driving the Rally and Is It Worth Buying in 2026?

Brent Spot $190 Warning: WTI Flips Global Benchmark in Rare Price Inversion as Geopolitical Tensions Flare

Tradingkey








